

Celia Oreja-Guevara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6807962/publications.pdf>

Version: 2024-02-01

144
papers

7,071
citations

71102

41
h-index

66911

78
g-index

167
all docs

167
docs citations

167
times ranked

7216
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Consenso de expertos sobre el uso de alemtuzumab en la práctica clínica diaria en España. <i>Neurología</i> , 2022, 37, 615-630. | 0.7 | 3 |
| 2 | Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. <i>Neurología (English Edition)</i> , 2022, 37, 615-630. | 0.4 | 3 |
| 3 | Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. <i>Multiple Sclerosis Journal</i> , 2022, 28, 480-486. | 3.0 | 32 |
| 4 | Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial. <i>European Journal of Neurology</i> , 2022, 29, 790-801. | 3.3 | 15 |
| 5 | Natural history and optic neuritis in multiple sclerosis. <i>Anales De Pediatría (English Edition)</i> , 2022, 96, 66-68. | 0.2 | 0 |
| 6 | Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103669. | 2.0 | 4 |
| 7 | The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456. | 3.0 | 16 |
| 8 | Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Pharmacoeconomics</i> , 2022, 40, 323-339. | 3.3 | 3 |
| 9 | Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. <i>Multiple Sclerosis Journal</i> , 2022, 28, 842-846. | 3.0 | 13 |
| 10 | 038... Pregnancy outcomes in patients treated with ocrelizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A25.2-A25. | 1.9 | 0 |
| 11 | Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2151-2153. | 3.0 | 7 |
| 12 | EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic. <i>European Journal of Neurology</i> , 2021, 28, 7-14. | 3.3 | 27 |
| 13 | Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective. <i>European Journal of Neurology</i> , 2021, 28, 3226-3229. | 3.3 | 13 |
| 14 | Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102641. | 2.0 | 26 |
| 15 | A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: The NeuroCOVID-19 Task Force of the European Academy of Neurology. <i>European Journal of Neurology</i> , 2021, 28, 3849-3855. | 3.3 | 14 |
| 16 | Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. <i>Annals of Neurology</i> , 2021, 89, 1088-1098. | 5.3 | 55 |
| 17 | Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, . | 1.1 | 41 |
| 18 | Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. <i>Journal of Medical Internet Research</i> , 2021, 23, e29558. | 4.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. <i>Journal of Neurology</i> , 2021, 268, 3961-3968. | 3.6 | 47 |
| 20 | Risk and outcomes of COVID-19 in patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 3712-3721. | 3.3 | 26 |
| 21 | 004...Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , . | | 0 |
| 22 | Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 208, 106180. | 4.7 | 21 |
| 23 | Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry. <i>PLoS ONE</i> , 2021, 16, e0258437. | 2.5 | 5 |
| 24 | Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110582. | 3.5 | 9 |
| 25 | Single-subject structural cortical networks in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1392-1401. | 3.0 | 10 |
| 26 | Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868. | 2.0 | 29 |
| 27 | Treatment response score to glatiramer acetate or interferon beta-1a. <i>Neurology</i> , 2020, 96, 10.1212/WNL.0000000000010991. | 1.1 | 6 |
| 28 | Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756. | 7.6 | 24 |
| 29 | Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019). <i>Multiple Sclerosis Journal</i> , 2020, 26, 859-868. | 3.0 | 2 |
| 30 | Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102158. | 2.0 | 8 |
| 31 | The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. <i>European Journal of Neurology</i> , 2020, 27, 1727-1737. | 3.3 | 90 |
| 32 | Family planning is the second most relevant factor for treatment decisions after disease activity " No. <i>Multiple Sclerosis Journal</i> , 2020, 26, 642-643. | 3.0 | 2 |
| 33 | Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population. <i>Journal of Neurology</i> , 2020, 267, 2362-2371. | 3.6 | 21 |
| 34 | Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study. <i>PLoS ONE</i> , 2020, 15, e0230846. | 2.5 | 9 |
| 35 | A call for a global COVID-19 Neuro Research Coalition. <i>Lancet Neurology</i> , The, 2020, 19, 482-484. | 10.2 | 22 |
| 36 | Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care. <i>Advances in Therapy</i> , 2019, 36, 3238-3252. | 2.9 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Cognitive Dysfunctions and Assessments in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 581. | 2.4 | 70 |
| 38 | Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. <i>Frontiers in Neurology</i> , 2019, 10, 253. | 2.4 | 17 |
| 39 | Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 8463-8470. | 7.1 | 112 |
| 40 | Antiphospholipid Antibodies Overlapping in Isolated Neurological Syndrome and Multiple Sclerosis: Neurobiological Insights and Diagnostic Challenges. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 107. | 3.7 | 18 |
| 41 | Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 32, 54-63. | 2.0 | 37 |
| 42 | Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243. | 2.0 | 35 |
| 43 | Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD). <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 7-14. | 2.0 | 10 |
| 44 | Biomarkers in Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a029058. | 6.2 | 88 |
| 45 | Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 352-360. | 3.0 | 22 |
| 46 | Vitamin D and remyelination in multiple sclerosis. <i>Neurología (English Edition)</i> , 2018, 33, 177-186. | 0.4 | 12 |
| 47 | Revisión sistemática sobre la eficacia y seguridad de los neuroestimuladores periféricos del ganglio esfenopalatino para el tratamiento de la cefalea crónica en racimos refractaria. <i>Neurología</i> , 2018, 36, 440-440. | 0.7 | 2 |
| 48 | Familial multiple sclerosis and association with other autoimmune diseases. <i>Brain and Behavior</i> , 2018, 8, e00899. | 2.2 | 11 |
| 49 | Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet, The</i> , 2018, 391, 1263-1273. | 13.7 | 684 |
| 50 | Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology, The</i> , 2018, 17, 405-415. | 10.2 | 238 |
| 51 | Vitamina D y remielinización en la esclerosis múltiple. <i>Neurología</i> , 2018, 33, 177-186. | 0.7 | 26 |
| 52 | Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018, 24, 590-603. | 3.0 | 101 |
| 53 | Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652. | 3.0 | 37 |
| 54 | Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 153-160. | 2.0 | 101 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641880324. | 3.5 | 16 |
| 56 | Three-Tesla MRI does not improve the diagnosis of multiple sclerosis. <i>Neurology</i> , 2018, 91, e249-e257. | 1.1 | 26 |
| 57 | Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276. | 3.0 | 30 |
| 58 | Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203. | 1.9 | 49 |
| 59 | Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. <i>Brain and Behavior</i> , 2017, 7, e00671. | 2.2 | 32 |
| 60 | Amyloid PET in pseudotumoral multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 15, 15-17. | 2.0 | 7 |
| 61 | Multimarker risk stratification approach at multiple sclerosis onset. <i>Clinical Immunology</i> , 2017, 181, 43-50. | 3.2 | 9 |
| 62 | Inhibition of neurogenesis in a case of Marburg variant multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 71-76. | 2.0 | 8 |
| 63 | Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology</i> , The, 2017, 16, 797-812. | 10.2 | 397 |
| 64 | Estimate of the cost of multiple sclerosis in Spain by literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 321-333. | 1.4 | 20 |
| 65 | Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017, 89, 1050-1059. | 1.1 | 38 |
| 66 | New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain. <i>Multiple Sclerosis Journal</i> , 2017, 23, 166-178. | 3.0 | 37 |
| 67 | Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. <i>CNS Drugs</i> , 2017, 31, 33-50. | 5.9 | 57 |
| 68 | Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1346-1357. | 3.0 | 18 |
| 69 | Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443. | 7.6 | 94 |
| 70 | Functional Components of Cognitive Impairment in Multiple Sclerosis: A Cross-Sectional Investigation. <i>Frontiers in Neurology</i> , 2017, 8, 643. | 2.4 | 40 |
| 71 | Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging. <i>Frontiers in Neurology</i> , 2016, 7, 53. | 2.4 | 44 |
| 72 | Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405. | 7.6 | 281 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Pittsburgh compound B and other amyloid positron emission tomography tracers for the study of white matter and multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 166-166. | 5.3 | 7 |
| 74 | Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349. | 1.9 | 63 |
| 75 | Neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e225. | 6.0 | 134 |
| 76 | Analysis of the Relationship between the Month of Birth and Risk of Multiple Sclerosis in a Spanish Population. <i>European Neurology</i> , 2016, 76, 202-209. | 1.4 | 9 |
| 77 | Intervenciones psicoterapéuticas y psicosociales para el manejo del estrés en esclerosis múltiple: aportación de intervenciones basadas en mindfulness. <i>Neurología</i> , 2016, 31, 113-120. | 0.7 | 10 |
| 78 | Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 574-584. | 10.2 | 266 |
| 79 | Psychotherapeutic and psychosocial interventions for managing stress in multiple sclerosis: The contribution of mindfulness-based interventions. <i>Neurología (English Edition)</i> , 2016, 31, 113-120. | 0.4 | 6 |
| 80 | The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532. | 3.0 | 34 |
| 81 | Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting. <i>Revista De Neurologia</i> , 2016, 62, 559-69. | 7.8 | 2 |
| 82 | Amyloid PET imaging in multiple sclerosis: an 18F-florbetaben study. <i>BMC Neurology</i> , 2015, 15, 243. | 1.8 | 58 |
| 83 | Comparative efficacy of switching to natalizumab in active multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 373-387. | 3.7 | 57 |
| 84 | Effects of diazoxide in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e147. | 6.0 | 8 |
| 85 | Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560019. | 1.0 | 5 |
| 86 | Spanish consensus on the use of natalizumab (Tysabri®)-2013. <i>Neurología (English Edition)</i> , 2015, 30, 302-314. | 0.4 | 6 |
| 87 | Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice. <i>European Journal of Neurology</i> , 2015, 22, 22-27. | 3.3 | 17 |
| 88 | Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435. | 5.3 | 143 |
| 89 | Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 202-218. | 2.0 | 85 |
| 90 | Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491. | 3.7 | 43 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Visual and statistical analysis of 18F-FDG PET in primary progressive aphasia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 916-927. | 6.4 | 35 |
| 92 | <scp>BREMSO</scp>: a simple score to predict early the natural course of multiple sclerosis. <i>European Journal of Neurology</i> , 2015, 22, 981-989. | 3.3 | 32 |
| 93 | Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405. | 9.0 | 100 |
| 94 | Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298. | 7.6 | 162 |
| 95 | Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171. | 3.0 | 36 |
| 96 | Consenso espaÃ±ol actualizado sobre el uso del natalizumab (Tysabri®)-2013. <i>NeurologÃ­a</i> , 2015, 30, 302-314. | 0.7 | 13 |
| 97 | Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015, 10, e0122686. | 2.5 | 122 |
| 98 | Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1511-1522. | 3.0 | 73 |
| 99 | Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 739-746. | 3.0 | 148 |
| 100 | Clinical Relevance of Brain Volume Measures in Multiple Sclerosis. <i>CNS Drugs</i> , 2014, 28, 147-156. | 5.9 | 254 |
| 101 | Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner. <i>Therapeutic Advances in Neurological Disorders</i> , 2014, 7, 137-149. | 3.5 | 9 |
| 102 | Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014, 76, 880-890. | 5.3 | 67 |
| 103 | Therapeutic Decisions in Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 1315-24. | 9.0 | 80 |
| 104 | Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study. <i>Journal of Neurology</i> , 2013, 260, 1258-1262. | 3.6 | 9 |
| 105 | Future MS care: a consensus statement of the MS in the 21st Century Steering Group. <i>Journal of Neurology</i> , 2013, 260, 462-469. | 3.6 | 27 |
| 106 | Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 55-59. | 2.8 | 39 |
| 107 | Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013, 136, 3609-3617. | 7.6 | 140 |
| 108 | Consensus statement on medication use in multiple sclerosis by the Spanish Society of Neurology's study group for demyelinating diseases. <i>NeurologÃ­a (English Edition)</i> , 2013, 28, 375-378. | 0.4 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Monitoring neuromyelitis optica activity. Expert Review of Neurotherapeutics, 2013, 13, 989-999. | 2.8 | 1 |
| 110 | Documento del Grupo de Consenso de la Sociedad Española de Neurología sobre el uso de medicamentos en esclerosis múltiple. Neurología, 2013, 28, 375-378. | 0.7 | 18 |
| 111 | Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. European Journal of Paediatric Neurology, 2013, 17, 50-54. | 1.6 | 45 |
| 112 | Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. PLoS ONE, 2013, 8, e63480. | 2.5 | 26 |
| 113 | Spasticity in multiple sclerosis: results of a patient survey. International Journal of Neuroscience, 2013, 123, 400-408. | 1.6 | 75 |
| 114 | Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe. Expert Review of Neurotherapeutics, 2013, 13, 61-66. | 2.8 | 4 |
| 115 | EXPOSURE TO INTERFERON- β THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A17.2-A17. | 1.9 | 2 |
| 116 | The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Multiple Sclerosis Journal, 2012, 18, 974-982. | 3.0 | 56 |
| 117 | The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 305-310. | 1.9 | 37 |
| 118 | Clinical efficacy and effectiveness of Sativex [®] , a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Review of Neurotherapeutics, 2012, 12, 3-8. | 2.8 | 24 |
| 119 | Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. Journal of Neurology, 2012, 259, 1814-1823. | 3.6 | 42 |
| 120 | PND65 Spanish Neurology Therapeutic Society Guidelines for the Treatment of Relapsing Remitting MS: Are They Followed by Spanish Neurologists?. Value in Health, 2012, 15, A557. | 0.3 | 0 |
| 121 | TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. BMC Neurology, 2012, 12, 95. | 1.8 | 108 |
| 122 | Consenso español sobre la utilización de natalizumab (Tysabri [®]) - 2011. Neurología, 2012, 27, 432-441. | 0.7 | 7 |
| 123 | Spanish consensus on the use of natalizumab (Tysabri [®]) - 2011. Neurología (English Edition), 2012, 27, 432-441. | 0.4 | 3 |
| 124 | Increasing age at disability milestones among MS patients in the MSBase Registry. Journal of the Neurological Sciences, 2012, 318, 94-99. | 0.6 | 35 |
| 125 | Clinically Isolated Syndromes Suggestive of Multiple Sclerosis: An Optical Coherence Tomography Study. PLoS ONE, 2012, 7, e33907. | 2.5 | 20 |
| 126 | Improving patient–physician dialog: commentary on the results of the MS Choices survey. Patient Preference and Adherence, 2012, 6, 143. | 1.8 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS ONE, 2012, 7, e38661. | 2.5 | 35 |
| 128 | Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. PLoS ONE, 2012, 7, e48078. | 2.5 | 166 |
| 129 | Outcome of patients with amyotrophic lateral sclerosis attending in a multidisciplinary care unit. Neurología (English Edition), 2011, 26, 455-460. | 0.4 | 9 |
| 130 | Optical Coherence Tomography in Multiple Sclerosis and Neuromyelitis Optica: An Update. Multiple Sclerosis International, 2011, 2011, 1-11. | 0.8 | 39 |
| 131 | Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. Journal of Immunological Methods, 2011, 371, 170-173. | 1.4 | 25 |
| 132 | Treatment with Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism. Journal of Clinical Immunology, 2011, 31, 623-631. | 3.8 | 44 |
| 133 | Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Therapeutic Advances in Neurological Disorders, 2011, 4, 139-168. | 3.5 | 76 |
| 134 | Descripción de una clínica para la atención a los pacientes con esclerosis múltiple. Neurología, 2010, 25, 156-162. | 0.7 | 3 |
| 135 | Neuritis óptica asociada o no a esclerosis múltiple: estudio estructural y funcional. Neurología, 2010, 25, 78-82. | 0.7 | 10 |
| 136 | Optic neuritis, multiple sclerosis-related or not: Structural and functional study. Neurología (English Edition), 2010, 25, 78-82. | 0.4 | 3 |
| 137 | Clinical pathways for the care of multiple sclerosis patients. Neurología (English Edition), 2010, 25, 156-162. | 0.4 | 5 |
| 138 | Burden and health-related quality of life of Spanish caregivers of persons with multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 1347-1355. | 3.0 | 81 |
| 139 | Magnetization Transfer Magnetic Resonance Imaging and Clinical Changes in Patients With Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2006, 63, 736. | 4.5 | 33 |
| 140 | Progressive Gray Matter Damage in Patients With Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2005, 62, 578. | 4.5 | 103 |
| 141 | The role of V5 (hMT+) in visually guided hand movements: an fMRI study. European Journal of Neuroscience, 2004, 19, 3113-3120. | 2.6 | 29 |
| 142 | Plasticity of cortical hand muscle representation in patients with hemifacial spasm. Neuroscience Letters, 1999, 272, 33-36. | 2.1 | 24 |
| 143 | Analysis of lymphocyte subpopulations in cerebrospinal fluid and peripheral blood in patients with multiple sclerosis and inflammatory diseases of the nervous system. Acta Neurologica Scandinavica, 1998, 98, 310-313. | 2.1 | 30 |
| 144 | A longitudinal study of circulating lymphocyte subsets in the peripheral blood during the acute stage of Guillain-Barré syndrome. Journal of the Neurological Sciences, 1997, 151, 29-34. | 0.6 | 23 |